Last reviewed · How we verify

NCT03277131

DURAFIBER Ag Post-Market Clinical Follow-Up

Completed NA Last updated 2 March 2022
What this trial tests

NA trial testing DURAFIBER Ag in Wounds and Injuries in 20 participants. Completed in 19 June 2019.

Timeline
12 December 2017
Primary endpoint
19 June 2019
19 June 2019

Quick facts

Lead sponsorSmith & Nephew, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date12 December 2017
Primary completion19 June 2019
Estimated completion19 June 2019
Sites7 locations across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Smith & Nephew, Inc. — full company profile →

Who can join

18 and older, any sex, with Wounds and Injuries or Venous Leg Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the performance of DURAFIBER Ag and to assess how many bacteria are present in infected wounds over an 8 week period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Wounds and Injuries

Currently open trials in the same condition.

Other Smith & Nephew, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03277131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing